Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Characterization and Comparison of GITR Expression in Solid Tumors.

Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Sai T, Chaparro-Riggers J, Subudhi SK, B Scutti J, Higa MG, Zhao H, Yadav SS, Maitra A, Wistuba II, Allison JP, Sharma P.

Clin Cancer Res. 2019 Jul 29. doi: 10.1158/1078-0432.CCR-19-0289. [Epub ahead of print]

PMID:
31358539
2.

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.

Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales MA, Merghoub T, Houghton AN, Wolchok JD.

PLoS One. 2010 May 3;5(5):e10436. doi: 10.1371/journal.pone.0010436.

3.

HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.

Richards DM, Marschall V, Billian-Frey K, Heinonen K, Merz C, Redondo Müller M, Sefrin JP, Schröder M, Sykora J, Fricke H, Hill O, Gieffers C, Thiemann M.

J Immunother Cancer. 2019 Jul 19;7(1):191. doi: 10.1186/s40425-019-0671-4.

4.

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S.

J Exp Med. 2005 Oct 3;202(7):885-91. Epub 2005 Sep 26. Erratum in: J Exp Med. 2012 Feb 13;209(2):423.

5.

Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.

Scirka B, Szurek E, Pietrzak M, Rempala G, Kisielow P, Ignatowicz L, Miazek A.

Arch Immunol Ther Exp (Warsz). 2017 Dec;65(6):553-564. doi: 10.1007/s00005-017-0479-1. Epub 2017 Jun 21.

6.

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.

Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X.

J Transl Med. 2014 Feb 7;12:36. doi: 10.1186/1479-5876-12-36.

7.

Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.

Côté AL, Zhang P, O'Sullivan JA, Jacobs VL, Clemis CR, Sakaguchi S, Guevara-Patiño JA, Turk MJ.

J Immunol. 2011 Jan 1;186(1):275-83. doi: 10.4049/jimmunol.1001308. Epub 2010 Nov 24.

8.

GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.

van Beek AA, Zhou G, Doukas M, Boor PPC, Noordam L, Mancham S, Campos Carrascosa L, van der Heide-Mulder M, Polak WG, Ijzermans JNM, Pan Q, Heirman C, Mahne A, Bucktrout SL, Bruno MJ, Sprengers D, Kwekkeboom J.

Int J Cancer. 2019 Aug 15;145(4):1111-1124. doi: 10.1002/ijc.32181. Epub 2019 Feb 27.

9.

Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L.

Calmels B, Paul S, Futin N, Ledoux C, Stoeckel F, Acres B.

Cancer Gene Ther. 2005 Feb;12(2):198-205.

PMID:
15472713
10.

GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.

Durham NM, Holoweckyj N, MacGill RS, McGlinchey K, Leow CC, Robbins SH.

J Immunother Cancer. 2017 Jun 20;5:47. doi: 10.1186/s40425-017-0247-0. eCollection 2017.

11.

Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.

Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Kochman AA, Lu S, Miles RC, Sakaguchi S, Houghton AN, van den Brink MR.

J Immunol. 2006 Jun 1;176(11):6434-42.

12.

Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.

Shrimali R, Ahmad S, Berrong Z, Okoev G, Matevosyan A, Razavi GSE, Petit R, Gupta S, Mkrtichyan M, Khleif SN.

J Immunother Cancer. 2017 Aug 15;5(1):64. doi: 10.1186/s40425-017-0266-x.

13.

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.

Schaer DA, Budhu S, Liu C, Bryson C, Malandro N, Cohen A, Zhong H, Yang X, Houghton AN, Merghoub T, Wolchok JD.

Cancer Immunol Res. 2013 Nov;1(5):320-31. doi: 10.1158/2326-6066.CIR-13-0086.

14.

A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.

Leyland R, Watkins A, Mulgrew KA, Holoweckyj N, Bamber L, Tigue NJ, Offer E, Andrews J, Yan L, Mullins S, Oberst MD, Coates Ulrichsen J, Leinster DA, McGlinchey K, Young L, Morrow M, Hammond SA, Mallinder P, Herath A, Leow CC, Wilkinson RW, Stewart R.

Clin Cancer Res. 2017 Jul 1;23(13):3416-3427. doi: 10.1158/1078-0432.CCR-16-2000. Epub 2017 Jan 9.

15.

Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.

Mahne AE, Mauze S, Joyce-Shaikh B, Xia J, Bowman EP, Beebe AM, Cua DJ, Jain R.

Cancer Res. 2017 Mar 1;77(5):1108-1118. doi: 10.1158/0008-5472.CAN-16-0797. Epub 2016 Oct 20.

16.

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential.

Tigue NJ, Bamber L, Andrews J, Ireland S, Hair J, Carter E, Sridharan S, Jovanović J, Rees DG, Springall JS, Solier E, Li YM, Chodorge M, Perez-Martinez D, Higazi DR, Oberst M, Kennedy M, Black CM, Yan L, Schwickart M, Maguire S, Cann JA, de Haan L, Young LL, Vaughan T, Wilkinson RW, Stewart R.

Oncoimmunology. 2017 Feb 3;6(3):e1280645. doi: 10.1080/2162402X.2017.1280645. eCollection 2017.

17.

GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells.

Liao G, Nayak S, Regueiro JR, Berger SB, Detre C, Romero X, de Waal Malefyt R, Chatila TA, Herzog RW, Terhorst C.

Int Immunol. 2010 Apr;22(4):259-70. doi: 10.1093/intimm/dxq001. Epub 2010 Feb 5.

18.

Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity.

Cho JS, Hsu JV, Morrison SL.

Cancer Immunol Immunother. 2009 Jul;58(7):1057-69. doi: 10.1007/s00262-008-0622-2. Epub 2008 Nov 19.

19.

GITR Agonism Enhances Cellular Metabolism to Support CD8+ T-cell Proliferation and Effector Cytokine Production in a Mouse Tumor Model.

Sabharwal SS, Rosen DB, Grein J, Tedesco D, Joyce-Shaikh B, Ueda R, Semana M, Bauer M, Bang K, Stevenson C, Cua DJ, Zúñiga LA.

Cancer Immunol Res. 2018 Oct;6(10):1199-1211. doi: 10.1158/2326-6066.CIR-17-0632. Epub 2018 Aug 28.

20.

Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.

Aida K, Miyakawa R, Suzuki K, Narumi K, Udagawa T, Yamamoto Y, Chikaraishi T, Yoshida T, Aoki K.

Cancer Sci. 2014 Feb;105(2):159-67. doi: 10.1111/cas.12332. Epub 2014 Jan 4.

Supplemental Content

Support Center